440 / 1498
HL: the numbers
•
9200 cases estimated in US in 2013-SEER Data
•
Approximate numbers based upon MSKCC long term data (GHSG for
Early HL, IPI-based for Advanced HL)
–
Favorable Early HL: 15%
–
Unfavorable Early HL: 25%
–
Bulky stage II disease: 20%
–
Favorable Advanced HL (0-3 RF): 30%
–
Unfavorable Advanced HL (4-7 RF): 10%